β1-Integrin: A Potential Therapeutic Target in the Battle against Cancer Recurrence
- 30 November 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (23) , 7219-7223
Abstract
Primary cancer treatment, involving both local and often systemic adjuvant therapy, is often successful, especially if the cancer is detected at an early stage of progression. However, for some patients, the cancer may recur either locally or as distant metastases, in some cases many years after apparently successful primary treatment. Significant tumor dormancy has been documented in several cancers, such as breast, melanoma, and renal cancer. Tumor dormancy has long been recognized as an important problem in management of cancer patients. Recent work has clarified biologic aspects of tumor dormancy and has shown that dormant tumor cells may be resistant to cytotoxic chemotherapy and radiation. This work has led to recognition of a key role for β1-integrin in regulating the switch from a dormant state to active proliferation and metastasis. Here we discuss the role of β1-integrin and its signaling partners in regulating the dormant phenotype. We also consider possible therapeutic approaches, such as small molecules or antibodies (ATN-161, volociximab, and JSM6427), directed against β1-integrin signaling to target dormant cancer cells and to prevent metastatic recurrence. Clin Cancer Res; 17(23); 7219–23. ©2011 AACR.Keywords
This publication has 42 references indexed in Scilit:
- Three-Dimensional Imaging and Quantification of Both Solitary Cells and Metastases in Whole Mouse Liver by Magnetic Resonance ImagingCancer Research, 2009
- Integrin β 1 -focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungsProceedings of the National Academy of Sciences, 2009
- Inhibition of Metastatic Outgrowth from Single Dormant Tumor Cells by Targeting the CytoskeletonCancer Research, 2008
- Dual Function of Pancreatic Endoplasmic Reticulum Kinase in Tumor Cell Growth Arrest and SurvivalCancer Research, 2008
- Models, mechanisms and clinical evidence for cancer dormancyNature Reviews Cancer, 2007
- Requirement of KISS1 Secretion for Multiple Organ Metastasis Suppression and Maintenance of Tumor DormancyJNCI: Journal of the National Cancer Institute, 2007
- In vivo MRI of cancer cell fate at the single‐cell level in a mouse model of breast cancer metastasis to the brainMagnetic Resonance in Medicine, 2006
- Ineffectiveness of Doxorubicin Treatment on Solitary Dormant Mammary Carcinoma Cells or Late-developing MetastasesBreast Cancer Research and Treatment, 2003
- Dissemination and growth of cancer cells in metastatic sitesNature Reviews Cancer, 2002
- Urokinase Receptor and Fibronectin Regulate the ERKMAPK to p38MAPK Activity Ratios That Determine Carcinoma Cell Proliferation or Dormancy In VivoMolecular Biology of the Cell, 2001